论文部分内容阅读
CD70是肿瘤坏死因子受体(tumor necrosis factor receptor，TNFR)超家族的成员之一，目前的研究证实CD70主要表达于B细胞、活化的T细胞及成熟的树突状细胞中。CD70还高水平表达于多种血液肿瘤和实体瘤，使其可能成为肿瘤免疫治疗的潜在靶点。在过去的几十年，免疫学的进步使免疫检查点得以确定，这使得癌症免疫治疗再度成为热点。现就CD70在非小细胞肺癌(non-small cell lung cancer，NSCLC)中的相关研究进行回顾与总结，以期为CD70在NSCLC中的免疫治疗提供参考和研究依据。“,”CD70 is a member of tumor necrosis factor receptor (TNFR) super family.Current research has confirmed that it mainly expresses in B cells, activated T cells and mature dendritic cells.CD70 is also highly expressed in various hematologic and solid malignancies, making it a potential target for tumor immunotherapy.In the past few decades, the progress of immunology has enabled the identification of immune checkpoints, which makes cancer immunotherapy become a hot spot again.This paper reviews and summarizes the research progress of CD70 in non-small cell lung cancer(NSCLC), so as to provide beneficial references and research basis for immunotherapy of NSCLC.